Odyssean LLC purchased a new stake in Kenvue Inc. (NYSE:KVUE – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 27,730 shares of the company’s stock, valued at approximately $530,000.
Other large investors have also recently bought and sold shares of the company. Man Group plc acquired a new stake in Kenvue during the 2nd quarter worth $80,461,000. Polar Asset Management Partners Inc. acquired a new position in Kenvue in the second quarter valued at $7,744,000. Jupiter Topco LLC acquired a new position in Kenvue in the second quarter valued at $7,600,000. Kintayl Capital LP purchased a new stake in shares of Kenvue in the second quarter valued at about $7,094,000. Finally, Hsbc Holdings PLC boosted its stake in shares of Kenvue by 34.3% during the second quarter. Hsbc Holdings PLC now owns 7,544,394 shares of the company’s stock worth $143,893,000 after buying an additional 1,926,217 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.
Analyst Ratings Changes
KVUE has been the topic of a number of research reports. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. UBS Group reduced their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.27.
Kenvue Stock Down 0.5%
Shares of NYSE:KVUE opened at $19.23 on Thursday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $20.95. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm’s 50-day simple moving average is $19.12 and its 200-day simple moving average is $18.23. The company has a market cap of $36.94 billion, a price-to-earnings ratio of 22.10, a PEG ratio of 1.38 and a beta of 0.47.
Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The firm had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.29 earnings per share. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
See Also
- Five stocks we like better than Kenvue
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
